Related Experiment Videos
Drug-mediated immunogenic changes of virus-induced leukemia in vivo
Abstract:
LSTRA and RBL-5 lymphomas induced by Moloney and Rauscher leukemia viruses, respectively, were used to determine whether antigenically altered tumors induced by 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide in vivo would retain their original antigenic properties and/or have new antigenic properties. The tumors became highly immunogenic in the syngeneic hosts after 4 to 8 transplant generations with drug treatment. Syngeneic mice could be protected against challenge with the parental tumor by presensitization with the drug-altered sublines while unrelated tumor lines were incapable of protecting them. The drug-altered subline of LSTRA was used for treatment of the LSTRA in conjunction with chemotherapy, and this immunochemotherapy produced significant increases in number of survivors and increases in median survival time compared to either treatment alone. Tolerance studies indicated that there are novel antigens and parental tumor antigens associated with the drug-treated sublines.
Insights
Treatment with 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide altered lymphoma tumor antigens, enhancing immunogenicity. These altered tumors, when used with chemotherapy, significantly improved survival rates in mice.
Area of Science:
- Oncology
- Immunology
- Virology
Background:
- Lymphomas such as LSTRA and RBL-5 are induced by specific leukemia viruses.
- Investigating antigenicity changes in tumors after drug treatment is crucial for cancer therapy development.
Purpose of the Study:
- To determine if tumors induced by 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide retain original or acquire new antigenic properties.
- To evaluate the therapeutic potential of antigenically altered tumors in combination with chemotherapy.
Main Methods:
- Utilized LSTRA and RBL-5 lymphoma models in syngeneic mice.
- Administered 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide over multiple transplant generations.
- Assessed immunogenicity and protective effects of drug-altered tumor sublines.
- Conducted immunochemotherapy trials combining altered LSTRA sublines with chemotherapy.
Main Results:
- Drug treatment induced high immunogenicity in tumors after 4-8 transplant generations.
- Presensitization with altered sublines protected against parental tumor challenge.
- Immunochemotherapy significantly increased survival and median survival time compared to single treatments.
- Tolerance studies revealed both novel and parental tumor antigens on drug-treated sublines.
Conclusions:
- 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide treatment induces significant antigenic alterations in lymphoma tumors.
- Antigenically modified tumors possess therapeutic potential, especially when combined with chemotherapy.
- The altered tumors express both new and original tumor antigens, offering a dual approach for immunotherapy.